| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | RSS | TABLE OF CONTENTS |
|
|
|
||||||||
|
||||||||||
Special Contribution |
1 Department of Nuclear and Radiological Engineering, University of Florida, Gainesville, Florida; 2 Environmental Sciences Division, Oak Ridge National Laboratory, Oak Ridge, Tennessee; 3 Department of Radiology, Johns Hopkins Medical Institutions, Baltimore, Maryland; and 4 Department of Radiology, University of Cincinnati, Cincinnati, Ohio
Correspondence: For correspondence or reprints contact: Wesley E. Bolch, MIRD Committee, Department of Nuclear and Radiological Engineering, 202 Nuclear Science Center, University of Florida, Gainesville, FL 32611-8300. E-mail: wbolch{at}ufl.edu
The internal dosimetry schema of the Medical Internal Radiation Dose (MIRD) Committee of the Society of Nuclear Medicine has provided a broad framework for assessment of the absorbed dose to whole organs, tissue subregions, voxelized tissue structures, and individual cellular compartments for use in both diagnostic and therapeutic nuclear medicine. The schema was originally published in 1968, revised in 1976, and republished in didactic form with comprehensive examples as the MIRD primer in 1988 and 1991. The International Commission on Radiological Protection (ICRP) is an organization that also supplies dosimetric models and technical data, for use in providing recommendations for limits on ionizing radiation exposure to workers and members of the general public. The ICRP has developed a dosimetry schema similar to that of the MIRD Committee but has used different terminology and symbols for fundamental quantities such as the absorbed fraction, specific absorbed fraction, and various dose coefficients. The MIRD Committee objectives for this pamphlet are 3-fold: to restate its schema for assessment of absorbed dose in a manner consistent with the needs of both the nuclear medicine and the radiation protection communities, with the goal of standardizing nomenclature; to formally adopt the dosimetry quantities equivalent dose and effective dose for use in comparative evaluations of potential risks of radiation-induced stochastic effects to patients after nuclear medicine procedures; and to discuss the need to identify dosimetry quantities based on absorbed dose that address deterministic effects relevant to targeted radionuclide therapy.
Key Words: MIRD schema • ICRP schema • absorbed dose • equivalent dose • effective dose
In collaboration with the SNM MIRD Committee: Wesley E. Bolch, A. Bertrand Brill, Darrell R. Fisher, Roger W. Howell, Ruby Meredith, George Sgouros, Stephen R. Thomas (Chair), and Barry W. Wessels.
COPYRIGHT © 2009 by the Society of Nuclear Medicine, Inc.
Related articles in JNM:
This article has been cited by other articles:
|
|
 |
|
  W. B. Li and C. Hoeschen UNCERTAINTY AND SENSITIVITY ANALYSIS OF BIOKINETIC MODELS FOR RADIOPHARMACEUTICALS USED IN NUCLEAR MEDICINE Radiat Prot Dosimetry, February 25, 2010; (2010) ncq064v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Sgouros, J. C. Roeske, M. R. McDevitt, S. Palm, B. J. Allen, D. R. Fisher, A. B. Brill, H. Song, R. W. Howell, G. Akabani, et al. MIRD Pamphlet No. 22 (Abridged): Radiobiology and Dosimetry of {alpha}-Particle Emitters for Targeted Radionuclide Therapy J. Nucl. Med., February 1, 2010; 51(2): 311 - 328. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Andersson, E. Cederkrantz, T. Back, C. Divgi, J. Elgqvist, J. Himmelman, G. Horvath, L. Jacobsson, H. Jensen, S. Lindegren, et al. Intraperitoneal {alpha}-Particle Radioimmunotherapy of Ovarian Cancer Patients: Pharmacokinetics and Dosimetry of 211At-MX35 F(ab')2--A Phase I Study J. Nucl. Med., July 1, 2009; 50(7): 1153 - 1160. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | RSS | TABLE OF CONTENTS |
| JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY | THE JOURNAL OF NUCLEAR MEDICINE |
